Partnering With Pharmacists to Reduce Cardiovascular Risk in Outpatient Settings.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Statin therapy optimization in older adults: interim results of a randomized controlled trial of pharmacist-led pharmaceutical care.GeroScience · 2026
   Article
2. Bridging the gap: Enhancing pharmacist-physiscian collaboration through the provision of comprehensive medication reviews in community pharmacy.Exploratory research in clinical and social pharmacy · 2025
   Article
3. Role of community pharmacists in cardiovascular diseases-related health promotion and dyslipidemia management in Malaysia: A nationwide cross-sectional study.PloS one · 2023
   Article
4. Partnering With Pharmacists to Reduce Cardiovascular Risk in Outpatient Settings.Journal of the American Heart Association · 2019
   Article

Corrections and comments

• Comment on
  Systematic Review and Meta-Analysis of Medication Reviews Conducted by Pharmacists on Cardiovascular Diseases Risk Factors in Ambulatory Care.2019

Authors and funding

2 authors.

Funding

Abstract

Indexed as